Novel agents and combination therapies have been investigated by several studies in both the upfront and relapsed setting, particularly for patients with 17p deletion, TP53 mutation and fludarabine-refractory CLL. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.